Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI